UY39221A - Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos - Google Patents
Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismosInfo
- Publication number
- UY39221A UY39221A UY0001039221A UY39221A UY39221A UY 39221 A UY39221 A UY 39221A UY 0001039221 A UY0001039221 A UY 0001039221A UY 39221 A UY39221 A UY 39221A UY 39221 A UY39221 A UY 39221A
- Authority
- UY
- Uruguay
- Prior art keywords
- cov
- methods
- same
- sars
- selection
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002064 post-exposure prophylaxis Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente a la proteína espicular del SARS-CoV-2 y métodos para elaborar y seleccionar los mismos. Los anticuerpos pueden usarse, por ejemplo, en la profilaxis, profilaxis posterior a la exposición o tratamiento de la infección por SARS-CoV-2. Los anticuerpos también se pueden usar para detectar la infección por SARS-CoV-2 en un sujeto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063026121P | 2020-05-17 | 2020-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39221A true UY39221A (es) | 2021-12-31 |
Family
ID=76098926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039221A UY39221A (es) | 2020-05-17 | 2021-05-18 | Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos |
Country Status (19)
Country | Link |
---|---|
US (2) | US20210355196A1 (es) |
EP (1) | EP4153312A1 (es) |
JP (1) | JP2023528235A (es) |
KR (1) | KR20230010749A (es) |
CN (1) | CN115697491A (es) |
AR (1) | AR122111A1 (es) |
AU (1) | AU2021275361A1 (es) |
BR (1) | BR112022023088A2 (es) |
CA (1) | CA3182150A1 (es) |
CL (1) | CL2022003177A1 (es) |
CO (1) | CO2022017690A2 (es) |
CR (1) | CR20220646A (es) |
EC (1) | ECSP22094536A (es) |
IL (1) | IL297977A (es) |
MX (1) | MX2022014422A (es) |
PE (1) | PE20231376A1 (es) |
TW (1) | TW202208423A (es) |
UY (1) | UY39221A (es) |
WO (1) | WO2021233834A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020340881A1 (en) | 2020-04-02 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
CN116057069A (zh) | 2020-06-03 | 2023-05-02 | 瑞泽恩制药公司 | 用抗SARS-CoV-2刺突糖蛋白抗体治疗或预防SARS-CoV-2感染和COVID-19的方法 |
BR112023002234A2 (pt) * | 2020-08-10 | 2023-03-07 | Astrazeneca Uk Ltd | Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 |
WO2022263638A1 (en) * | 2021-06-17 | 2022-12-22 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
CA3225575A1 (en) * | 2021-07-14 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
WO2023141176A2 (en) * | 2022-01-19 | 2023-07-27 | Icahn School Of Medicine At Mount Sinai | Neutralizing antibodies and antigen-binding fragments thereof against omicron and other coronavirus variants, and methods of making and using the same |
TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Rq生物科技有限公司 | 抗體 |
CN115286712B (zh) * | 2022-03-18 | 2024-09-27 | 北京百普赛斯医学检验实验室有限公司 | 新型冠状病毒Delta突变株特异性抗体及其应用 |
CN116041494B (zh) * | 2022-12-12 | 2024-08-20 | 首都医科大学 | 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
EP2275541B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
WO2002000879A2 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
EA013224B1 (ru) | 2000-10-06 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Клетки, продуцирующие композиции антител |
EP1333032A4 (en) | 2000-10-06 | 2005-03-16 | Kyowa Hakko Kogyo Kk | METHOD FOR PURIFYING ANTIBODIES |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
ATE489395T1 (de) | 2000-12-12 | 2010-12-15 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
JP2005538706A (ja) | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ, | スーパーヒト化抗体 |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CA2478297C (en) | 2002-03-19 | 2013-05-14 | Plant Research International B.V. | Optimizing glycan processing in plants |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
KR101292000B1 (ko) | 2003-01-22 | 2013-08-01 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이증가된 항체를 생성하기 위한 이의 용도 |
EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
US8716557B2 (en) | 2006-01-17 | 2014-05-06 | Synthon Biopharmaceuticals B.V. | Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
BRPI0816785A2 (pt) | 2007-09-14 | 2017-05-02 | Adimab Inc | bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas |
BRPI1007005A2 (pt) | 2009-01-29 | 2016-03-22 | Medimmune Llc | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 |
KR102024922B1 (ko) | 2010-07-16 | 2019-09-25 | 아디맵 엘엘씨 | 항체 라이브러리 |
HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
MX2022011142A (es) * | 2020-03-09 | 2022-12-13 | Abcellera Biologics Inc | Anticuerpos anti-coronavirus y metodos de uso. |
WO2021203053A1 (en) * | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
-
2021
- 2021-05-17 MX MX2022014422A patent/MX2022014422A/es unknown
- 2021-05-17 KR KR1020227044127A patent/KR20230010749A/ko active Search and Examination
- 2021-05-17 BR BR112022023088A patent/BR112022023088A2/pt unknown
- 2021-05-17 WO PCT/EP2021/063008 patent/WO2021233834A1/en active Application Filing
- 2021-05-17 CR CR20220646A patent/CR20220646A/es unknown
- 2021-05-17 AR ARP210101350A patent/AR122111A1/es unknown
- 2021-05-17 PE PE2022002684A patent/PE20231376A1/es unknown
- 2021-05-17 US US17/322,137 patent/US20210355196A1/en not_active Abandoned
- 2021-05-17 AU AU2021275361A patent/AU2021275361A1/en active Pending
- 2021-05-17 EP EP21727793.8A patent/EP4153312A1/en active Pending
- 2021-05-17 IL IL297977A patent/IL297977A/en unknown
- 2021-05-17 CA CA3182150A patent/CA3182150A1/en active Pending
- 2021-05-17 JP JP2022569523A patent/JP2023528235A/ja active Pending
- 2021-05-17 TW TW110117697A patent/TW202208423A/zh unknown
- 2021-05-17 CN CN202180035990.0A patent/CN115697491A/zh active Pending
- 2021-05-18 UY UY0001039221A patent/UY39221A/es unknown
-
2022
- 2022-11-15 CL CL2022003177A patent/CL2022003177A1/es unknown
- 2022-12-06 CO CONC2022/0017690A patent/CO2022017690A2/es unknown
- 2022-12-13 EC ECSENADI202294536A patent/ECSP22094536A/es unknown
-
2023
- 2023-11-30 US US18/524,769 patent/US20240182548A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202208423A (zh) | 2022-03-01 |
AU2021275361A1 (en) | 2023-01-19 |
CL2022003177A1 (es) | 2023-07-28 |
IL297977A (en) | 2023-01-01 |
EP4153312A1 (en) | 2023-03-29 |
CN115697491A (zh) | 2023-02-03 |
WO2021233834A1 (en) | 2021-11-25 |
CR20220646A (es) | 2023-10-23 |
US20210355196A1 (en) | 2021-11-18 |
ECSP22094536A (es) | 2023-01-31 |
CO2022017690A2 (es) | 2022-12-20 |
AR122111A1 (es) | 2022-08-17 |
BR112022023088A2 (pt) | 2022-12-20 |
CA3182150A1 (en) | 2021-11-25 |
JP2023528235A (ja) | 2023-07-04 |
PE20231376A1 (es) | 2023-09-07 |
US20240182548A1 (en) | 2024-06-06 |
MX2022014422A (es) | 2022-12-07 |
KR20230010749A (ko) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22094536A (es) | Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos | |
ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
CO2020016559A2 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
ECSP21022299A (es) | Anticuerpos de anti-cd33 y métodos para usarlos | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
ECSP23019525A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
CL2020003168A1 (es) | Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis | |
CO2022010204A2 (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
CL2023001052A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea | |
DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
CL2021002169A1 (es) | Métodos para obtener células de músculo liso inducidas | |
EA201991716A1 (ru) | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ГЕНТИНГТОНА | |
CL2022000752A1 (es) | Molécula de unión específica para lif y uso de la misma | |
CL2018001873A1 (es) | Anticuerpos igy para la prevención de infestación e infección de liendres marinas | |
BR112021018611A2 (pt) | Anticorpos tendo especificidade para btn2 e usos dos mesmos | |
EA202190361A1 (ru) | Лечение рецидивирующей фолликулярной лимфомы | |
CL2022002938A1 (es) | Formulación sistémica de un derivado de la piridinona para la enfermedad celíaca | |
EA202191388A1 (ru) | Лечение головной боли при избыточном применении лекарственных препаратов антителами к cgrp или cgrp-r | |
AR104931A1 (es) | Métodos para tratar cáncer usando anticuerpos anti-ox40 y antagonistas de unión al eje pd-1 | |
AR116106A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
EA201991135A1 (ru) | Комбинированная терапия ингибиторами аргиназы |